Compare
TG Therapeutics, Inc. vs Opko Health, Inc. vs Insmed Inc vs Axsome Therapeutics, Inc.
| Latest fiscal year | TG Therapeutics, Inc. TGTX | Opko Health, Inc. OPK | Insmed Inc INSM | Axsome Therapeutics, Inc. AXSM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $616.29M | $606.88M | $606.42M | $638.50M |
| Revenue growth (YoY) | +87.3% | -14.9% | +66.7% | +65.5% |
| Gross margin | 83.7% (computed) | 33.9% | 79.7% (computed) | n/a |
| Operating margin | 20.0% | -19.3% | -205.6% | -26.1% |
| Net margin | 72.6% | -37.2% | -210.5% | -28.7% |
| Net income | $447.18M | -$225.68M | -$1.28B | -$183.17M |
| EPS (Diluted) | $2.77 | -$0.30 | -$6.42 | -$3.68 |
| Operating cash flow | -$24.77M | -$178.54M | -$935.01M | -$93.41M |
| Free cash flow | -$24.99M | -$190.82M | -$967.58M | -$93.89M |
| Cash & equivalents | $79.15M | $364.41M | $510.44M | $322.93M |
| Total assets | $1.06B | $1.93B | $2.26B | $689.80M |
| Total liabilities | $415.23M | $663.99M | $1.53B | $601.51M |
| Shareholders' equity | $648.02M | $1.27B | $738.98M | $88.30M |
| Return on year-end equity | 69.0% | -17.8% | -172.8% | -207.5% |
| Shares outstanding | 155.31M | n/a | 214.26M | 50.88M |
Revenue, most recent five fiscal years
| Fiscal year | TG Therapeutics, Inc. | Opko Health, Inc. | Insmed Inc | Axsome Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $616.29M Ended 2025-12-31 | $606.88M Ended 2025-12-31 | $606.42M Ended 2025-12-31 | $638.50M Ended 2025-12-31 |
| 1 year earlier | $329.00M Ended 2024-12-31 | $713.14M Ended 2024-12-31 | $363.71M Ended 2024-12-31 | $385.69M Ended 2024-12-31 |
| 2 years earlier | $233.66M Ended 2023-12-31 | $863.50M Ended 2023-12-31 | $305.21M Ended 2023-12-31 | $270.60M Ended 2023-12-31 |
| 3 years earlier | $2.79M Ended 2022-12-31 | $1.00B Ended 2022-12-31 | $245.36M Ended 2022-12-31 | $50.04M Ended 2022-12-31 |
| 4 years earlier | $6.69M Ended 2021-12-31 | $1.77B Ended 2021-12-31 | $188.46M Ended 2021-12-31 | n/a |